Please login to the form below

PharmaMar

This page shows the latest PharmaMar news and features for those working in and with pharma, biotech and healthcare.

PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19

However, PharmaMar added that while the toxicity is a ‘concern’, the doses used in its COVID-19 clinical trials are well tolerated in humans. ... PharmaMar added in a statement that it is discussing the launch of phase 3 trials with different

Latest news

Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Jazz licensed lurbinectedin from
NICE recommends two drugs for ovarian cancer but rejects three

But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.
FDA approves Janssen’s Yondelis

Luis Mora, managing director of Janssen's licensing partner PharmaMar, said: “Since Yondelis was first approved in Europe in 2007 approximately 50, 000 patients in 80 countries have benefited from this
PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

Cancer drug could be approved in the US within months. PharmaMar's cancer drug Yondelis could be approved in the US within a few months after it was fast-tracked by ... would be "financially transformative" for PharmaMar's parent company Zeltia.
NICE rejection of three ovarian cancer drugs stands

NICE has over the past three years rejected three medicines for the disease: Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan), both of which are also available as generics, and

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest appointments

Bedrock hires new client services director

Patricia has combined her scientific and commercial understanding to work strategically with both large and small clients, including most recently Novartis, Abbott, Astellas, Bristol-Myers Squibb, PharmaMar and Roche, and we

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Account Management: Competitive Salary Offered

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...